Jan 27, 2024 · The MZL-IPI is the first validated prognostic index designed for the whole spectrum of newly diagnosed symptomatic MZLs that integrates histology and disease dissemination …

In both the training and the validation studies, MZL-IPI was associated with the best prediction and discrimination performance, as compared to the IPI, FLIPI and MALT-IPI, and was also …

Dec 9, 2022 · Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas and include 3 different subtypes—namely, extranodal (EMZL), nodal, and splenic …

Sep 21, 2017 · Compare prognostic features incorporated in the mucosa-associated lymphoid tissue lymphoma international prognostic index (MALT-IPI). Evaluate the ability of the MALT …

Disease overview: Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma. Diagnosis: Three subtypes of MZL are recognized: splenic, …

Apr 11, 2024 · The proposed MZL International Prognostic index (MZL-IPI) combined these 5 factors, and we defined low (LRG, 0 factors, 27%), intermediate (IRG, 1-2 factors, 57%) and …

Jan 6, 2020 · This index, named MALT-IPI, uses three simple clinical parameters (age ≥70 years, Ann Arbor stage III or IV and elevated LDH) and allows the discrimination of three groups of …

Feb 10, 2025 · For assessing MZL as a single entity in patients in need of systemic therapy, the MZL-IPI score includes LDH, absolute lymphocyte count, hemoglobin, platelets, and nodal …

Mar 15, 2025 · The International Prognostic Index (IPI), though designed for aggressive lymphomas, has some applicability in MZL, particularly nodal cases. More specific models, …

Conclusions: MZL‐IPI is a new validated prognostic score for all patients with MZL who are considered for systemic treatment. Introduction: Fluorodeoxyglucose (FDG)‐PET/CT is the …